-Did the authors develop a conceptual model relating functional vision and O&M? If so, this would be very be helpful to include. -page 4/line 44: the authors could consider specifying here that they are (I believe) referring to both instruments --VROOM and OMO --when they stateo "Part A" and "Part B." It is helpful for the reader to know this without referencing the appendix to learn that both instruments contain these parts.
-page 5/line 21: consider specifying what statistical analyses were used to test the unidimensionality of VROOM (e.g. principle components or confirmatory factor analysis) -page 5/line 28: it sounds as if OMO was not found to test a single construct, is this correct? If so, the authors might consider explicitly stating this and describing the different domains that they believe the instrument is measuring at present.
-page 7: the authors discuss some of the advantages and drawbacks of various technologies used by people with low vision or blindness. They might consider framing this discussion through the lens of "human factors engineering," a discipline that uses principles of engineering and psychology to improve the user-centered design of products and technologies.
-statistical power is mentioned several times in the text, as well as in Table 1 . Are you able to discuss in more detail how the study is powered? That is, do you have a sense of how much of a change measured with VROOM and/or OMO is clinically meaningful; if not, how will this be determined (e.g. relative to quantitative measures of criterion validity or in another manner altogether given the co-rated and mixed data)?
-page 11/line 31-32: Might the instruments need to be recalibrated in different cultural and/or geographic contexts? This could of course be tested with the data collected in Malaysia. IRT/Rasch modeling could be helpful in this regard and the authors may consider mentioning this. -page 13/line 33: please check this web address, as it does not appear to be valid when I tried to access it. Appendix -please consider defining all abbreviations at the bottom of each table strong focus on *what* is done, and not so much on the why and for what purpose and how it will be validated in the future. This is more what I would expect from this type of publication? The title of this MS seems to imply the paper is indeed on a protocol. Perhaps the authors can focus the text. 
SPECIFIC

GENERAL COMMENTS
I do have major concerns with the studies themselves, however, even though I know it is not the task of this review to critique studies -especially since they have not yet been carried out. So for now I just have major concerns about the presentation of the background, instruments, and interpretation of expected findings that should be addressed to improve the quality of the MS, and potentially of the study. Some of these concerns may only be answered once the study has been conducted, but they should be recognized as potential limitations of the protocol and/or pitfalls of the methodology. The first item in the list, for example, is presumably meant as a strength ("addressing an international shortage…"), but it is also a limitation since it encompasses almost everything one could wish to measure in O&M ("functional vision and functional mobility skills of people of any age or abilities").
"aggregate ratings to a single comparable score") are supposedly Strengths (although this is not stated), but one can certainly question whether that latter should not be phrased as conditional, since it is purely hypothetical that such a single score will be a meaningful outcome.
is completely unclear. Do the authors mean "take precedence over" ? If so, what does this mean? Is it a strength or a weakness?
considered an industry in Australia? Would "field partners" be a better term?) collecting data is a statement of fact, and thus neither a strength or a weakness. Do the authors mean to say that this gives the data a basis in reality (which would be a strength, but also a minimum requirement) ? explain why there are 2 instruments that on careful scrutiny are identical for the O&M portion, and not very different for the Wellbeing portion. It is true that this portion of the VROOM explores functional aspects of vision (although not following one of the well-established categorizations, such as functional domains or visual objectives, but an apparent subset of the goals in the Activity Breakdown Structure), while the corresponding section of the OMO deals with 2 O&M-related aspects without explicitly mentioning vision (Life-Space and Orientation) and 3 that are more generally related to quality of life. Yet this does not diminish the concern that the two outcomes will be very highly correlated, to the point where the reader may wonder why the two are not combined into a single instrument. This is something the authors definitely need to explain in the Introduction.
The listing in Table 1 of validity criteria 5 -7 raises important questions: o Under Content Validity, how does one develop interpretation tables for a combined (VROOM or OMO) score without first analyzing whether the combined score is meaningful metric (i.e., construct validity), let alone "identify relevant constructs that have not yet been measured" ? o Under Construct Validity, the authors want to demonstrate unidimensionality of the partial scores, but they do not proposa to use an exploratory factor analysis or principal components analysis, to approaches that immediately come to mind for such an endeavor.
o Under Criterion validity, combined VROOM scores will be correlated with visual acuity in the better eye (n=65), while combined OMO scores will be correlated for concurrent validity with the results of the Client Evaluation Tool (n=85). Why not correlate both instruments with both independent measures? justification for sample sizes. The stratification into 6 levels of vision seems reasonable, but there is no indication that the authors have determined what sample sizes would be adequate. To give just one example why equal sample sizes are unlikely to be optimal: The scores in the middle of the range will most likely reveal the greatest heterogeneity between subjects, and those scores are most likely to come from the middle cohorts, so those cohorts should be large than the highest and lowest ones. In addition to these misgivings about the presentation in its current form, there are 2 items in the MS that need attention: Please leave your comments for the authors below This is a well-prepared manuscript that provides a description of an observational study in which the authors' newly developed outcome measures will be applied and validated.
Response: Thanks for the compliment. Comment: page 4/line 44: the authors could consider specifying here that they are (I believe) referring to both instruments --VROOM and OMO --when they stateo "Part A" and "Part B." It is helpful for the reader to know this without referencing the appendix to learn that both instruments contain these parts.
Response: We have clarified this section. On Page 6 Main Doc, line 8ff, description of Part A has been supplemented with detail about the two different rating scales used to measure vision (VROOM ratings based on sensory preferencing) and O&M (OMO ratings based on travel competence).
Comment: page 5/line 21: consider specifying what statistical analyses were used to test the unidimensionality of VROOM (e.g. principle components or confirmatory factor analysis) -page 5/line 28: it sounds as if OMO was not found to test a single construct, is this correct? If so, the authors might consider explicitly stating this and describing the different domains that they believe the instrument is measuring at present.
Response: Thank you for picking up this omission. We used exploratory factor analysis and have added this detail to Page 6, line 35 along with a little more explanation about the elements of the OMO tool that raised questions during our analyses of pilot data.
Comment: page 7: the authors discuss some of the advantages and drawbacks of various technologies used by people with low vision or blindness. They might consider framing this discussion through the lens of "human factors engineering," a discipline that uses principles of engineering and psychology to improve the user-centered design of products and technologies.
Response: Thank you for this helpful suggestion. A paragraph has been included in the technology section (Page 8, line 40ff) to reference human factors engineering, in particular co-design and ethnographic analysis which have particular relevance to the design and evaluation of assistive technology.
Comment: statistical power is mentioned several times in the text, as well as in Table 1 . Are you able to discuss in more detail how the study is powered?
Response: We added explanation on Page 14, line 24ff, that we have two sampling perspectives. Theoretical warranting using grounded theory methodology is the priority and depends less on sample size and more on data saturation. We included more detail on Page 14, line 38ff about the basis on which we have estimated sample sizes.
Comment: That is, do you have a sense of how much of a change measured with VROOM and/or OMO is clinically meaningful; if not, how will this be determined (e.g. relative to quantitative measures of criterion validity or in another manner altogether given the co-rated and mixed data)?
Response: The question of what signifies "meaningful change" is related to the second phase of data collection looking at pre-post training comparisons, and a sentence has been added to the data collection section on Page 17, line 26. Meaningful change will be determined (1) by individual participants, evident in their comments recorded alongside their co-ratings, (2) through grounded theory methodology as comments and scores are analysed theoretically to understand what constitutes meaningful change, and (3) as descriptive statistics show the range of change associated with selected intervention groups. We expect the range of change will vary in magnitude because the bionic eye prototype resulted in a 12-16% increase in VROOM score whereas a corneal graft resulted in a 60% increase in VROOM score. These considerations have already been discussed in the existing text.
Comment: page 11/line 31-32: Might the instruments need to be recalibrated in different cultural and/or geographic contexts? This could of course be tested with the data collected in Malaysia. IRT/Rasch modeling could be helpful in this regard and the authors may consider mentioning this.
Response: Thanks for raising this important issue. In this study, we don't anticipate collecting sufficient numerical data from the Malaysian context to statistically recalibrate the VROOM and OMO tools. The emphasis during the Malaysian cultural study is on qualitative inquiry to (1) understand issues relating to low vision, blindness, independence and disability in Malaysia that affect perceptions of functional performance, (2) work with Malaysian partners to revise grounded theories that underpin the VROOM and OMO tools, and then (3) revise the VROOM and OMO tools to suit the Malaysian context. Formal VROOM/OMO data collection followed by IRT/Rasch modelling is certainly worthwhile, but needs to follow this grounded theory phase and is beyond the scope of the current protocol. The recruitment section of Methods has been amended to make this clear on Page 16, line 25.
Comment: page 13/line 33: please check this web address, as it does not appear to be valid when I tried to access it.
Response: Thank you for picking this up. The link we included has been deleted since first submission of this paper, but we have provided another link and the name of the Malaysian guide dog user so that interested readers can follow his story online -Page 16, line 13ff. Appendix Comment: please consider defining all abbreviations at the bottom of each Please leave your comments for the authors below Comment: While I find this topic worthy of investigation, personally, I do not find study design papers such as this worthwhile endeavors. By and large, they don't provide any novel information to the literature and much of the information will be reiterated once the study is completed and the results published. The value of such studies might be extended if the authors used it as an opportunity to revise the study design and protocol, but commenting on those issues once the study is underway becomes a waste of time, as does questioning the need/justification for the study. Thus, I am not supportive of publishing this paper, but this should not be mistaken for concerns about the design and need for the study, both of which are reasonable.
Response: Thank you Professor McGwin for your perspective. We believe a protocol paper is useful in this context for several reasons. (1) Our study is the first of its kind to concentrate in functional vision rather than clinical vision and mobility. (2) We are using a novel constructivist approach to measuring functional performance which we believe is the only congruent way forward in this research domain. (3) Our research path runs counter to all assumptions in the O&M literature to date about how O&M outcome studies should be conducted, and it needs to be theoretically justified. (4) Potential industry partners have said they see this direction as a positive solution to problems that have plagued O&M outcome measurement to date, and have asked for publications that explain this novel approach. (5) We are a strong multidisciplinary research team that seeks to be transparent about our long-term research map in this high cost/low incidence field of inquiry to avoid unnecessary waste of research resources. (6) We wish to equip the O&M profession to streamline assessment practices, while also fostering collaboration between O&M Specialists and eye/vision researchers to gain maximum international benefit from this combination of professional and research resources.
Reviewer: 3
Reviewer Name: H. Christiaan Stronks Institution and Country: Leiden University Medical Center, Netherlands Please state any competing interests: None declared Please leave your comments for the authors below 148626
Comment: This MS describes two protocols to assess O&M in terms of low vision. It is a potentially interesting paper given the trend towards standardization in the low-vision community. It is generally well-written, but to me it seems that a protocol paper needs to have focus on the protocol. As of now there is an overwhelming amount of text dedicated to perspectives where the authors frame how and where their work lies within rehab of low vision, as well as how the authors have set up the protocol, and how they are planning to implement it in the future and how they are going to validate it etc. Perhaps the authors have specific purpose for the wordiness of the MS, but to me they seem side tracks obscuring the goal of the MS, namely describing a protocol.
Response: Clinical protocols are typically spare in their introductory description because they share common assumptions about research design (e.g., that objectivity is possible when measuring functional performance, that research tasks and venues should be standardised to minimise confounding variables). Our research protocol contests these assumptions, asserting that functional research is different to clinical inquiry. Mixed methods papers are often criticised for their lack of theory and justification for the research design. These differences in research paradigm require explanation, otherwise the reader can only evaluate our functional research protocol through the lens of a clinical research paradigm, perpetuating methodological incongruence and misunderstandings. We have reworked the text in the introduction to be more concise where possible, particularly in the Introduction, pages 3-8. Response: We have included more detailed descriptions of the VROOM and OMO tools in the Introduction, Page 5, line 9ff. They are now described as suites of behaviourally anchored rating scales, and similarities and differences in their respective rating scales are included.
Comment: To me, the reader seems to be continuously reading in an effort to finally find out what the MS is all about and the text obscures the message, or so it seems. If this was intentional, the authors may wish to consider re-defining the purpose in the abstract. The abstract indeed seems to imply that the MS outlines a plan as to how the protocols will be validated? But that is not the main goal of a BMJ protocol MS? For example, a random sample protocol paper can be found at http://bmjopen.bmj.com/content/6/1/e010156 . This paper has a strong focus on *what* is done, and not so much on the why and for what purpose and how it will be validated in the future. This is more what I would expect from this type of publication? The title of this MS seems to imply the paper is indeed on a protocol. Perhaps the authors can focus the text.
Response: We discuss reasons why this protocol is not highly standardised and prescriptive like the sample the reviewer has suggested for comparison, in the introduction, drawing a distinction between clinical and functional inquiry on page 4, lines 41-52 -functional inquiry needs to follow the participants' cues to adequately address the research question. We also discuss reasons why functional measures of vision and O&M are needed (1) by the O&M profession and (2) for translational medical research in the introduction on Page 4, line 56ff.
SPECIFIC
There are references to related work that may be relevant:
Response: Thank you for these suggestions. We have now referenced the three publications below in our introduction (Page 4, line 14ff), explaining why these clinical approaches to O&M research have little bearing on the functional vision and real-world O&M we are investigating in our protocol. al. This is a generally well-written MS about a study protocol to develop two O&M-related observational instruments in studies at centers in Australia and Malaysia. The authors explain the structure of the two instruments as well as the background and provide enough information to allow duplication of the study elsewhere; in this sense they meet the requirements one would expect from a MS in this category. I do have major concerns with the studies themselves, however, even though I know it is not the task of this review to critique studies -especially since they have not yet been carried out. So for now I just have major concerns about the presentation of the background, instruments, and interpretation of expected findings that should be addressed to improve the quality of the MS, and potentially of the study. Some of these concerns may only be answered once the study has been conducted, but they should be recognized as potential limitations of the protocol and/or pitfalls of the methodology.
To start with the presentation: • The listing of Strengths and Limitations does not provide a clear enumeration of what are strengths, and what are limitations. The first item in the list, for example, is presumably meant as a strength ("addressing an international shortage…"), but it is also a limitation since it encompasses almost everything one could wish to measure in O&M ("functional vision and functional mobility skills of people of any age or abilities").
Response: We have revised the list of strengths and limitations (Page 2, line 48ff) to make their differences clearer.
• The next 2 points ("aligning with O&M assessment practice" and "aggregate ratings to a single comparable score") are supposedly Strengths (although this is not stated), but one can certainly question whether that latter should not be phrased as conditional, since it is purely hypothetical that such a single score will be a meaningful outcome.
Response: We agree that adding together the VROOM and OMO scores out of 50 to a total out of 100 would produce a meaningless number. This was never our intention, but we realised that the phrase "single comparable score" could be interpreted this way. We have revised the wording in the list of strengths and limitations (Page 3, Line 8ff), and in subsequent text including the supplementary data, Appendix 1, where this inference might have been drawn. Subscales in the VROOM tool will be aggregated to a single score out of 50 for functional vision, and subscales in the OMO tool will be aggregated to a single score our of 50 for O&M, so that vision and mobility scores can be compared.
• The 4th statement "authenticity presiding over standardization…." is completely unclear. Do the authors mean "take precedence over" ? If so, what does this mean? Is it a strength or a weakness?
Response: We agree that this statement was unclear and have deleted it. We have included a new statement that highlights the strengths and limitations of generating co-rated data in this study (Page 3, Lines 13-18).
• The dependence on "industry partners" (is O&M training really considered an industry in Australia? Would "field partners" be a better term?) collecting data is a statement of fact, and thus neither a strength or a weakness. Do the authors mean to say that this gives the data a basis in reality (which would be a strength, but also a minimum requirement) ?
Response: "Industry partners" is a generic term that Swinburne University uses when engaging with research partners in any field external to the university. This statement has been amended to show that although it should be possible to meet the quota of assessments required, this commitment from industry partners is costly in a period of significant change in the O&M industry (Page 3, Line 20-25).
•
The presentation of the VROOM and OMO tools does not explain why there are 2 instruments that on careful scrutiny are identical for the O&M portion, and not very different for the Wellbeing portion.
Response: Part A is not identical in the VROOM and OMO tools -they use the same context, but different rating scales to score how the traveller achieves the five universal travel functions visually (VROOM) and then physically irrespective of vision (OMO). This has been clarified on Page 6, line 8ff of the main document with description of the two different rating scales in Part A included. The constructs investigated in Part B of both tools has also been listed in the text to highlight the distinction between functional vision and functional O&M. It is true that this portion of the VROOM explores functional aspects of vision (although not following one of the well-established categorizations, such as functional domains or visual objectives, but an apparent subset of the goals in the Activity Breakdown Structure), while the corresponding section of the OMO deals with 2 O&M-related aspects without explicitly mentioning vision (Life-Space and Orientation) and 3 that are more generally related to quality of life. Yet this does not diminish the concern that the two outcomes will be very highly correlated, to the point where the reader may wonder why the two are not combined into a single instrument. This is something the authors definitely need to explain in the Introduction.
Response: Grounded theory methodology is used when the established literature is inadequate to account for a phenomenon, and so a fresh perspective is generated from raw participant data about lived experience. This work was undertaken as a foundation for the VROOM and OMO tools, because the well-established categorisations for functional domains, visual objectives and activities were inadequate to account for functional vision and O&M. It is not clear why the reviewer assumes that VROOM and OMO scores will be highly correlated (although this is a common assumption from eye care professionals), in the face of published evidence and the experience of the O&M profession to the contrary. We have been careful to point out from the beginning of the article (Page 3, line 35ff) that vision and mobility are separate functional phenomena, and need to be measured separately because vision doesn't predict O&M capability (Lepri, 2009 ). In our pilot study with guide dog clients, there was little relationship between VROOM and OMO scores in participants' data, and the two most capable travellers (OMO 49 and 50) were completely blind (VROOM 0). We anticipate that our current protocol will identify whether there is more relationship between vision and mobility in some O&M client groups than in others. We have made no amendment to the text as a result of this comment from the reviewer.
• Another concern is in the interpretation and analysis of the data. The listing in Table 1 of validity criteria 5 -7 raises important questions: o Under Content Validity, how does one develop interpretation tables for a combined (VROOM or OMO) score without first analyzing whether the combined score is meaningful metric (i.e., construct validity), let alone "identify relevant constructs that have not yet been measured" ?
Response: We apologise for our lack of clarity prompting the misleading notion that we would add VROOM and OMO scores together. As we explained in Response 17, we have no intention of doing this and agree it would generate a meaningless number. We have amended table 1 under content validity (Page 11, column 2, line 33) to clarify that we will "Use qualitative data to: Develop separate interpretation tables for the VROOM and OMO tools." We have already begun drafting the interpretation table for VROOM from pilot data, but a larger, more diverse data-set is needed to complete this process and to develop the OMO interpretation table. o Under Construct Validity, the authors want to demonstrate unidimensionality of the partial scores, but they do not propose a to use an exploratory factor analysis or principal components analysis, to approaches that immediately come to mind for such an endeavor.
Response: Thank you for pointing this out. We do plan to use exploratory factor analysis to understand the data before investigating the unidimensionality of the tools. The table has been amended accordingly (Page 12, column 2, line 11).
o Under Criterion validity, combined VROOM scores will be correlated with visual acuity in the better eye (n=65), while combined OMO scores will be correlated for concurrent validity with the results of the Client Evaluation Tool (n=85). Why not correlate both instruments with both independent measures?
Response: Since first submitting our article, the opportunity to generate CET data for comparison with VROOM and OMO data has been closed through circumstances beyond our control relating to industry partners. We have deleted the CET reference from the criterion validity objective, but added that we will compare VROOM and OMO data with lifestyle data in addition to clinical visual acuity (Page 12, column 2, line 22). There are no gold standard measures in this field, but we have identified the value of comparisons with spatial cognition, self-rated travel skills and confidence if these data become available (Page 13, line 11-17).
In this last example, as elsewhere in the protocol, there is no justification for sample sizes. The stratification into 6 levels of vision seems reasonable, but there is no indication that the authors have determined what sample sizes would be adequate. To give just one example why equal sample sizes are unlikely to be optimal: The scores in the middle of the range will most likely reveal the greatest heterogeneity between subjects, and those scores are most likely to come from the middle cohorts, so those cohorts should be large than the highest and lowest ones.
Response: A priority in this study is to establish that the VROOM and OMO tools work effectively with the widest possible range of people. Our guide dog pilot cohort was skewed towards ultra-low vision (VROOM 0-40 out of 50), and more elite travel (OMO 24-50 out of 50), but still showed a surprising spread across the VROOM and OMO spectra. Consistent with grounded theory methodology, we are deliberately not formulating hypotheses about the heterogeneity or otherwise of participants. We will wait to see what the data tell us about participants' functional capabilities in each of the ten-point categories in each tool. To that end, as noted in Response 6, we are quota sampling for theoretical data saturation as much as statistical comparisons, and have clarified this in the section called "Sampling strategy and sample sizes" (Page 14, line 22ff). In addition to these misgivings about the presentation in its current form, there are 2 items in the MS that need attention: 
GENERAL COMMENTS
The authors have done an excellent job responding to the reviewers' critiques, and the MS is much easier to follow. While this clarifies many issues, it has also brought to light some additional issues that should be explained/justified, or modified.
One such issue becomes clear when looking at the VROOM and OMO questionnaire sheets and the corresponding instructions for assessors in Appendix 1. The assessors are told to mark the highest level of ECS encountered during the observed performance, but the score sheet does not say this, raising the concern that this will not be done consistently. So the score sheet should probably say "Highest ECS: 1 2 3 4 5 6"
Regardless of this marking, the scoring for both the VROOM and the OMO is likely to depend on performance at all ECS levels encountered during the observation, and since the prevalence of those levels may be out of the assessor's control (a rural evaluation may not provide levels 5 and 6, and possibly not even level 4), and particularly the OMO, but in dynamic conditions also the VROOM, will be scored differently depending on the prevalent ECS level(s) during the evaluation. In order to assess whether scores from different assessors and in different environments are comparable, video recordings of a representative sample of evaluations may be necessary. These concerns can be addressed by careful analysis of the data, but it is important to recognize them from the outset.While the Introduction is much better organized and easier to follow, it introduces several concepts that do not seem to be necessary, or at least are not supported by literature references. The first is the listing of 6 characteristics of functional inquiry (authenticity, embodiment, community, diversity, integration and learning), for which the first author's dissertation is given as the source. It is unclear how important these characteristics are for the introduction of the VROOM and OMO, or for the design of the study protocol; if they are, this should be clarified; if they are not, then I would suggest that they be removed. The second concept is that of the 3 manifestations of functional vision presented in Fig.1 . This tripartite representation of functional vision lumps hand-eye coordination and other visual motor interactions into near vision, which if acceptable but not necessarily logical; however, it ignores visual information gathering that can be distant, yet not related to O&M: watching a sunset, looking for a familiar person around a table, watching a play or a sporting event, etc. The distinction between near and distance vision is irrelevant in this regard; what is relevant is the function vision serves. How functional vision is conceptualized does not seem critical for the approach embodied by the VROOM and OMO, however; only the portion of Fig. 1 related to O&M is important. This becomes very clear in lines 18-21 of p. 6, where the difference between VROOM and OMO is explained as measuring different "aspects of function" (rather than "phenomena" which is a meaningless term in this context).
Rather than the qualitative approach in Fig.1 that largely deals with concepts not addressed by the VROOM, and not at all by the OMO, the MS would benefit from a timeline that lays out the different phases of data collection and the different types of analysis and instrument revisions that are envisaged. The development of O&M technology comes across as being an afterthought, and little detail is provided, other than the mentioning of 2 PhD projects, and a suggestion that this technology can help in the data collection for the VROOM and OMO instruments; how this technology plays a role in the validation study does not become clear.
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